The Glucagon-Like Peptide-1 (Glp-1) Analogs Market can be segmented into two major applications: T2DM and obesity. T2DM is the major application for GLP-1 analogs and accounts for the majority of the market share. GLP-1 analogs are used in the treatment of T2DM to improve glycemic control and reduce the risk of cardiovascular disease. GLP-1 analogs have also been shown to promote weight loss in patients with T2DM.
Obesity is a growing application for GLP-1 analogs. GLP-1 analogs have been shown to promote weight loss by reducing appetite and increasing feelings of fullness. GLP-1 analogs are also believed to reduce the absorption of calories from food. Liraglutide is the only GLP-1 analog that has been approved for the treatment of obesity, but other GLP-1 analogs are being investigated for their potential in this application.
Read More:
https://knackersblogger.blogspot.com/2023/03/glucagon-like-peptide-1-glp-1-analogs.html
